Trimethylammonium

Trimethylammonium

SCHEMBL2507791

CN(C)C.CN(C)C.CN(C)C.CN(C)C.CN(C)C.CN(C)C.Cl.Cl.Cl.Cl.Cl.Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Trimethylammonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10784388-B2 Photovoltaic devices with depleted heterojunctions and shell-passivated nanoparticles THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-09-22 US claimed
US-20160372616-A1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES INNOVATION ASSET COLLECTIVE (CA) 2016-12-22 US claimed
EP-2556131-A1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES The Governing Council Of The University Of Toronto (CA) 2013-02-13 EP claimed
WO-2011126778-A1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2011-10-13 WO claimed
US-20110240106-A1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2011-10-06 US claimed
US-10784388-B2 Photovoltaic devices with depleted heterojunctions and shell-passivated nanoparticles THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2020-09-22 US disclosed
US-20190077116-A1 FOAMED ACRYLIC-RESIN OBJECT, PROCESS FOR PRODUCING SAME, AND FIBER-REINFORCED COMPOSITE SEKISUI PLASTICS CO., LTD. (JP) 2019-03-14 US disclosed
EP-3348611-A1 FOAMED ACRYLIC-RESIN OBJECT, PROCESS FOR PRODUCING SAME, AND FIBER-REINFORCED COMPOSITE Sekisui Plastics Co., Ltd. (JP) 2018-07-18 EP disclosed
US-20160372616-A1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES INNOVATION ASSET COLLECTIVE (CA) 2016-12-22 US disclosed
CN-106167704-A Electrooptical device, nano-particle and the method forming nano-particle 多伦多大学董事局 2016-11-30 CN disclosed
CN-102859710-B Optoelectronic devices, nanoparticles, and methods of forming nanoparticles 多伦多大学董事局 2016-10-19 CN disclosed
EP-2556131-B1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES UNIV TORONTO (CA) 2016-10-12 EP disclosed
CN-102859710-A Photovoltaic device with depletion heterojunction and shell-passivated nanoparticles UNIV TORONTO 2013-01-02 CN disclosed
WO-2011126778-A1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2011-10-13 WO disclosed
US-20110240106-A1 PHOTOVOLTAIC DEVICES WITH DEPLETED HETEROJUNCTIONS AND SHELL-PASSIVATED NANOPARTICLES THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) 2011-10-06 US disclosed
EP-1354036-B1 COMPOSITIONS, METHODS, AND KITS FOR ISOLATING NUCLEIC ACIDS USING SURFACTANTS AND PROTEASES LIFE TECHNOLOGIES CORP (US) 2010-05-26 EP disclosed
US-7303876-B2 Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases APPLERA CORPORATION (US) 2007-12-04 US disclosed
US-7001724-B1 Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases APPLERA CORPORATION (US) 2006-02-21 US disclosed
US-20050009045-A1 Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases APPLERA CORPORATION 2005-01-13 US disclosed
US-6762027-B2 EXTRACTING PREFERENTIAL NUCLEOTIDE SEQUENCE FROM TISSUE; OBTAIN TISSUE SAMPLE, EXPOSE TO DISRUPTION MIXTURE, BIND NUCLEIC ACID TO SOLID PHASE, RECOVER NUCLEOTIDE SEQUENCES APPLERA CORPORATION 2004-07-13 US disclosed